Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Management of Rising PSA After Abiraterone Discontinuation in High-Risk Localized Prostate Cancer

Introduction to Management

  • The National Comprehensive Cancer Network recommends restarting androgen deprivation therapy (ADT) immediately with a GnRH analog and strongly considering adding enzalutamide 160 mg daily as combination therapy for patients with rising PSA after abiraterone discontinuation 1

Clinical Reasoning and Algorithm

  • A patient meets criteria for biochemical recurrence after radiation therapy if they have three consecutive PSA rises documented, with a short PSA doubling time, and PSMA-PET findings showing suspicious pelvic uptake despite stable conventional imaging 2
  • The American College of Radiology suggests that a PSA doubling time of less than 6 months is high-risk, and early hormonal therapy is indicated in such cases 4
  • The European Society for Medical Oncology states that PSA doubling time appears to be approximately 3-4 months, which is high-risk, and testosterone recovery should be confirmed before restarting ADT 4, 5

Risk Stratification

  • Patients with short PSA doubling time (<6 months) have rapid progression and prostate cancer-specific mortality, according to the Annals of Oncology 4, 5
  • PSMA-PET positive disease indicates active disease requiring systemic therapy, as per the Annals of Oncology 7
  • Prior high-risk localized disease and rising PSA kinetics despite prior intensive therapy are high-risk features mandating immediate treatment, as recommended by the National Comprehensive Cancer Network 1, 8

Treatment Selection

  • The National Comprehensive Cancer Network recommends ADT + enzalutamide combination therapy as the primary treatment for high-risk biochemical recurrence, with enzalutamide 160 mg orally once daily and GnRH analog (Lupron) per standard dosing 1
  • Early hormonal therapy is indicated for short PSA doubling time (<12 months) after local treatments, and delaying ADT until symptomatic disease is inappropriate, as stated by the Annals of Oncology 4

Monitoring Plan

  • PSA monitoring every 3 months initially, with a target of PSA <0.2 ng/mL within 6-12 months of treatment initiation, and repeat PSMA-PET at 6 months to assess response of PSMA-avid lesions to systemic therapy, as recommended by the Annals of Oncology 7
  • Testosterone monitoring to confirm castrate levels (<50 ng/dL) achieved with ADT reinitiation, according to the Journal of Clinical Oncology 2, 3